BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp.
Your view on BCT.TO
Overview
What the company does, where it operates, and who runs it.
About BriaCell Therapeutics Corp.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- William V. Williams FCPA,
- Headquarters
- Bellevue Centre, West Vancouver, BC, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- William V. Williams FCPA,
- Headquarters
- Bellevue Centre, West Vancouver, BC, CA
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab.
The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types.
It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer.
BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for BriaCell Therapeutics Corp., and the rating behind it. BCT.TO last traded at C$5.04; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for BriaCell Therapeutics Corp.. Starting points for BriaCell Therapeutics Corp.: EPS -C$4.23, beta 1.53 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for BriaCell Therapeutics Corp.. BriaCell Therapeutics Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for BriaCell Therapeutics Corp.. Trailing twelve-month EPS for BriaCell Therapeutics Corp. stands at -C$4.23. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for BriaCell Therapeutics Corp.. BriaCell Therapeutics Corp. has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
BriaCell Therapeutics Corp. valued side by side against its closest peers. BriaCell Therapeutics Corp. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold BriaCell Therapeutics Corp., and how their positions are changing. At a C$43.8M market value, institutional positions materially move BriaCell Therapeutics Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by BriaCell Therapeutics Corp. executives and directors. Shares of BriaCell Therapeutics Corp. have traded between C$8.40 and C$274.50 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming BriaCell Therapeutics Corp.. BriaCell Therapeutics Corp. is a C$43.8M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming BriaCell Therapeutics Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for BriaCell Therapeutics Corp.. Coverage tracks BriaCell Therapeutics Corp. within Biotechnology (Healthcare). Press releases and market coverage, newest first.